No significant OS advantage was found among CDK4/6 inhibitors for HR-positive, HER2-negative metastatic breast cancer. Real-world data showed median OS of 54.6 months for Ibrance, 59 months for ...
Gynecological cancers with amplifications in the CCNE1 gene, which encodes cyclin E1, usually exhibit resistance to standard therapies. Since cyclin-dependent kinase 2 (CDK2) is the primary partner of ...
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast ...
A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic breast cancer, presented at SABCS 2024. A retrospective study analyzing ...
California-based automotive technology company Tekion has sued its larger competitor CDK Global, accusing it of monopolizing the market for dealership management systems. Automotive tech company ...
ETX-197/BG-68501 is a highly potent inhibitor of Cyclin Dependent Kinase 2 (CDK2) with superior (~100x) selectivity for CDK2 over other CDK family members - - Preclinical in vivo studies demonstrated ...
Fortunately, theorists Robert Brout, François Englert and Peter Higgs made a proposal that was to solve this problem. What we now call the Brout-Englert-Higgs mechanism gives a mass to the W and Z ...
Pre-arbitration mechanisms are dispute resolution/prevention steps embodied in contracts between parties providing for an attempt at amicable resolution of the dispute. Parties have to abide by these ...
This study, the SONIA trial, showed that delaying and shortening the duration of a specific anti-cancer therapy (CDK4/6 inhibitors) in patients with hormone receptor-positive advanced breast ...